Home Tags Mylotarg

Tag: Mylotarg

Anti-CLL-1 ADC May Offer Effective and Safe Treatment Options for Patients...

Over the last 40 years treatment of acute myeloid leukemia or AML has not significantly changed.Today, the standard of care for AML is treatment...

FDA Approval for Gemtuzumab Ozogamicin: Reintroduction Based on Favorable Risk:Benefit Profile

The U.S. Food and Drug Administration (FDA) has approved gemtuzumab ozogamicin (Mylotarg™, previously known as CMA-676; Wyeth Pharmaceuticals, a subsidiary of Pfizer) for the...

Antibody-drug Conjugates: Technologies and Global Markets

Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new.  Due to many technological advances, recognition of appropriate target antigens, success...

Market Growth, Demand, Trends and Share of Antibody-drug Conjugates (2017 –...

A report published by Persistence Market Research (PMR), a U.S.-based full-service market intelligence firm specializing in syndicated research, shows that the global market for...

What to Expect at PEGS Boston 2017: A New Pathway of...

From the Charlestown Navy Yard to the Paul Revere House, the Old State House on Washington Street, the New England Aquarium at Central Wharf...

Pfizer Resubmits Application for Gemtuzumab Ozogamicin to European and American Regulators

In late January 2017 Pfizer's Biologics License Application (BLA) for gemtuzumab ozogamicin (Mylotarg®; previously known as CMA-676) was accepted for filing by the U.S....
Drugs & Durg Hunters

Drugs and Drug Hunters

All products of the creative process are a reflection of the individual makeup of the inventors.  A painting by Mark Rothko looks like a...

Looking Ahead to 2020: Global Antibody-drug Market Prediction

Cytotoxic drugs used in the treatment of solid tumors and hematological malignancies have, over the last 50 years, changed the natural progression of these...